Skip to main content
. 2014 Jun 16;8(3):1307–1311. doi: 10.3892/ol.2014.2255

Figure 4.

Figure 4

Effect of p38 MAPK inhibition on TβRII transcriptional levels in the JEG-3 cell line. Cells were divided into six groups: Control group, TGF-β1 group, 1-μM SB203580, 3-μM SB203580, 1-μM LY364947 and 3-μM LY364947 groups. Cells were pretreated with different concentrations of p38 MAPK and TGF-β1 receptor inhibitors, and cultured for 2 h,. Following this, 5 ng/ml TGF-β1 was added to cells in all groups except the control group, and incubation was continued for 2 h. The mRNA expression levels of TβRII were determined by reverse transcription quantitative real-time polymerase chain reaction. Results are presented as the mean ± SD from at least three independent experiments (P<0.05). MAPK, mitogen-activated protein kinase; TGF-β1, transforming growth factor β1; TβRI, TGF-β receptor type II. *P<0.05 vs. control group; ΔP<0.01 vs. TGF-β1 group.